Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.
about
Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelAssociation of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
P2860
Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Impact of dose de-escalation a ...... isolates in an in vitro model.
@en
Impact of dose de-escalation a ...... isolates in an in vitro model.
@nl
type
label
Impact of dose de-escalation a ...... isolates in an in vitro model.
@en
Impact of dose de-escalation a ...... isolates in an in vitro model.
@nl
prefLabel
Impact of dose de-escalation a ...... isolates in an in vitro model.
@en
Impact of dose de-escalation a ...... isolates in an in vitro model.
@nl
P2093
P2860
P356
P1476
Impact of dose de-escalation a ...... isolates in an in vitro model.
@en
P2093
Celine Vidaillac
Michael J Rybak
Molly E Steed
P2860
P304
P356
10.1128/AAC.01291-10
P407
P577
2011-02-14T00:00:00Z